EADS & HEALD WEALTH MANAGEMENT Buys 2, Sells 3 in 4th Quarter

EADS & HEALD WEALTH MANAGEMENT recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.

The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.

2100 RIVEREDGE PARKWAY NW STE 760 ATLANTA, GA 30328

As of the latest 13F report, the guru’s equity portfolio contained 145 stocks valued at a total of $197.00Mil. The top holdings were

According to GuruFocus data, these were EADS & HEALD WEALTH MANAGEMENT’s top five trades of the quarter.

Charles River Laboratories International Inc


The guru established a new position worth 2,851 shares in NYSE:CRL, giving the stock a 0.32% weight in the equity portfolio. Shares traded for an average price of $218.37 during the quarter.

On 01/28/2023, Charles River Laboratories International Inc traded for a price of $245.09 per share and a market cap of $12.36Bil. The stock has returned -21.33% over the past year.

GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 9 out of 10.

In terms of valuation, Charles River Laboratories International Inc has a price-earnings ratio of 28.87, a price-book ratio of 4.75, a price-earnings-to-growth (PEG) ratio of 1.86, a EV-to-Ebitda ratio of 17.82 and a price-sales ratio of 3.25.

The price-to-GF Value ratio is 0.79, earning the stock a GF Value rank of 9.

Crown Holdings Inc


During the quarter, EADS & HEALD WEALTH MANAGEMENT bought 4,770 shares of NYSE:CCK for a total holding of 9,389. The trade had a 0.2% impact on the equity portfolio. During the quarter, the stock traded for an average price of $79.7.

On 01/28/2023, Crown Holdings Inc traded for a price of $88.45 per share and a market cap of $10.49Bil. The stock has returned -20.68% over the past year.

GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 8 out of 10.

In terms of valuation, Crown Holdings Inc has a price-book ratio of 6.37, a EV-to-Ebitda ratio of 53.21 and a price-sales ratio of 0.82.

The price-to-GF Value ratio is 0.62, earning the stock a GF Value rank of 8.

Verisk Analytics Inc


EADS & HEALD WEALTH MANAGEMENT reduced their investment in NAS:VRSK by 1,874 shares. The trade had a 0.18% impact on the equity portfolio. During the quarter, the stock traded for an average price of $175.72.

On 01/28/2023, Verisk Analytics Inc traded for a price of $180.15 per share and a market cap of $27.92Bil. The stock has returned -3.62% over the past year.

GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 10 out of 10.

In terms of valuation, Verisk Analytics Inc has a price-earnings ratio of 27.97, a price-book ratio of 14.21, a price-earnings-to-growth (PEG) ratio of 3.50, a EV-to-Ebitda ratio of 17.95 and a price-sales ratio of 9.41.

The price-to-GF Value ratio is 0.92, earning the stock a GF Value rank of 7.

CBRE Group Inc


EADS & HEALD WEALTH MANAGEMENT reduced their investment in NYSE:CBRE by 4,061 shares. The trade had a 0.16% impact on the equity portfolio. During the quarter, the stock traded for an average price of $73.84999999999999.

On 01/28/2023, CBRE Group Inc traded for a price of $84.45999999999999 per share and a market cap of $26.59Bil. The stock has returned -11.57% over the past year.

GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 9 out of 10.

In terms of valuation, CBRE Group Inc has a price-earnings ratio of 13.94, a price-book ratio of 3.37, a price-earnings-to-growth (PEG) ratio of 1.33, a EV-to-Ebitda ratio of 9.29 and a price-sales ratio of 0.89.

The price-to-GF Value ratio is 0.97, earning the stock a GF Value rank of 6.

Salesforce Inc


EADS & HEALD WEALTH MANAGEMENT reduced their investment in NYSE:CRM by 1,637 shares. The trade had a 0.13% impact on the equity portfolio. During the quarter, the stock traded for an average price of $145.92.

On 01/28/2023, Salesforce Inc traded for a price of $164.52 per share and a market cap of $163.90Bil. The stock has returned -22.80% over the past year.

GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 7 out of 10.

In terms of valuation, Salesforce Inc has a price-earnings ratio of 587.57, a price-book ratio of 2.75, a price-earnings-to-growth (PEG) ratio of 22.01, a EV-to-Ebitda ratio of 39.71 and a price-sales ratio of 5.48.

The price-to-GF Value ratio is 0.57, earning the stock a GF Value rank of 4.


Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.

When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.

Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!

This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.